Search results for "Coma"

showing 10 items of 1084 documents

Pathophysiological Aspects of Glucose Uptake by the Tumor Tissue under Various Conditions of Oxygen and Glucose Supply

1976

Earlier examinations of the glucose uptake in neoplastic tissue by isolated DS- Carcinosarcoma implanted into the rat kidney had the results as follows (VAUPEL, 1974): 1. An increase of the tumor mass from 3 to 13 g wet weight caused an exponential decrease of the glucose consumption by the tumor tissue from 44.4 to 6.7/umoles per 100 g/min; very young tumors of 3 – 4 g bad uptake rates from 27.8 to 44.4/umoles/100 g/min. 2. Simultaneous measurements of the mean actual glucose concentrations in the tumor tissue showed that in the very young tumors the concentration still ranged from 1.75 to 2.25/umoles/g wet weight, whereas those in old tumors drop as low as 0 to 0.17/umoles/g.

medicine.medical_specialtyChemistryGlucose uptakechemistry.chemical_elementCarbohydrate metabolismmedicine.diseaseOxygenTumor tissuePathophysiologyEhrlich ascites carcinomaEndocrinologyInternal medicineCarcinosarcomamedicineGlycolysis
researchProduct

Behandlung der ausgeprägten Pubertätsgynäkomastie mit Tamoxifen

1987

Based on the good results of another author 10 boys with marked pubertal gynecomastia were treated with the antioestrogen Tamoxifen (Nolvadex) at a dose of 20-40 mg/d orally for 2-12 months. In most cases the gynecomastia decreased totally, only two patients experienced palpable subareolar glandular tissue at the end of therapy. Side effects were not noted. During therapy levels of estradiol and testosteron increased, with a more pronounced elevation of estradiol. Basal values of LH and FSH remained nearly unchanged, but LH showed an increased response to LH-RH, which could be explained by the antioestrogenic effect of Tamoxifen at the hypothalamic level. The reduction of breast size in spi…

medicine.medical_specialtyChemotherapyEnd of therapybusiness.industrymedicine.medical_treatmentTherapeutic effectEstrogen receptormedicine.diseaseBlockadeBasal (phylogenetics)EndocrinologyGynecomastiaInternal medicinePediatrics Perinatology and Child Healthmedicineskin and connective tissue diseasesbusinesshormones hormone substitutes and hormone antagonistsTamoxifenmedicine.drugKlinische Pädiatrie
researchProduct

Primary paraesophageal Ewing’s sarcoma: an uncommon case report and literature review

2015

Ewing’s sarcoma is a rare and highly aggressive cancer most frequently arising in people under 20 years of age. We report an uncommon case of primary paraesophageal Ewing’s sarcoma in a 25-year-old male harboring the infrequent EWSR1/ERG fusion transcript with multiple splice variants coexisting in the same tumor. The patient was totally refractory to chemotherapy and died 17 months after diagnosis. We underscore the need for better understanding of the molecular pathogenesis of the disease and improved systemic therapy options.

medicine.medical_specialtyChemotherapyPathologyrecurrenceParaesophagealbusiness.industrymedicine.medical_treatmentMolecular pathogenesisEwing's sarcomaCase ReportDiseasemedicine.diseaseDermatologySystemic therapyOncologyFusion transcriptimmunohistochemistryMedicinePharmacology (medical)SarcomaEwing’s sarcomabusinessfusion genesOncoTargets and Therapy
researchProduct

Prognostic factors in the treatment of Ewing's sarcoma

1987

From 1981 up to February 1985, a total of 93 protocol patients entered the study CESS 81. The protocol recommended an initial 18-week period of polychemotherapy (VACA) followed by local therapy and two additional cycles of chemotherapy. Local therapy consisted either of radical surgery or of incomplete resection plus postoperative irradiation with 36 Gy or of radiotherapy alone (46 and 60 Gy). Centrally located lesions were always irradiated with 60 Gy. This article summarizes the data after 5 years. Data of 93 patients were analysed in October 1986 after a median follow-up of 37 months. The projected 5-year survival is 50%. The relapse rate was 42%, distant relapses occurred in 19%, local …

medicine.medical_specialtyChemotherapybusiness.industryPaediatric oncologymedicine.medical_treatmentPostoperative irradiationEwing's sarcomaHematologymedicine.diseaseSurgeryRadiation therapyOncologyMedicineCombined Modality TherapyRadiology Nuclear Medicine and imagingSarcomaRadical surgerybusinessRadiotherapy and Oncology
researchProduct

The Effect of Erythropoietin on Tumor Oxygenation in Normal and Anemic Rats

1994

Anemia associated with malignancy is a common clinical problem. Its etiology is varied and includes nutritional causes, hemorrhage, hemolysis, bone marrow metastasis and hypoplasia, paraneoplastic syndromes, and chemotherapy1, with many patients presenting with anemia even before they receive cytotoxic therapy and even if their bone marrow is not invaded by tumor cells2. The response of tumors to standard radiotherapy and oxygen-dependent chemotherapy in these patients is often less satisfactory than in subjects with normal hemoglobin levels3. This is presumed to be due to the worsening of tumor oxygenation as a result of the decreased oxygen-carrying capacity of the blood in these anemic t…

medicine.medical_specialtyChemotherapymedicine.diagnostic_testbusiness.industryAnemiamedicine.medical_treatmentTumor OxygenationHematocritmedicine.diseaseMalignancyGastroenterologymedicine.anatomical_structureErythropoietinInternal medicinemedicineBone marrowSarcomabusinessmedicine.drug
researchProduct

Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (…

2015

ABSTRACT The DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) aims to provide recommendations for definitions of time-to-event end points in cancer randomized controlled trials. We relied on a consensus method based on a multidisciplinary panel of experts to develop these guidelines for trials on sarcomas and gastrointestinal stromal tumors. Background The use of potential surrogate end points for overall survival, such as disease-free survival (DFS) or time-to-treatment failure (TTF) is increasingly common in randomized controlled trials (RCTs) in cancer. However, the definition of time-to-event (TTE) end points is rarely precise and lacks unif…

medicine.medical_specialtyConsensusTime FactorssarcomaDelphi TechniqueEndpoint Determination[SDV]Life Sciences [q-bio]Disease-Free Survivallaw.invention03 medical and health sciencesgastrointestinal stromal tumors0302 clinical medicineRandomized controlled trialSDG 3 - Good Health and Well-beinglawMultidisciplinary approachTerminology as TopicmedicineHumansMedical physicsTreatment Failureguidelinestime-to-event end pointComputingMilieux_MISCELLANEOUSRandomized Controlled Trials as Topic030304 developmental biologyEvent (probability theory)0303 health sciencesEnd pointGiSTSurrogate endpointbusiness.industryefficacy measureCancerHematologymedicine.disease3. Good healthOncologyResearch Design030220 oncology & carcinogenesisrandomized controlled trialDisease ProgressionRadiologySarcomabusiness
researchProduct

Queratitis bacteriana por Moraxella nonliquefaciens

2020

Moraxella keratitis can lead to important complications. Moraxella nonliquefaciens(M. nonliquefaciens) has the worst prognosis. Only three cases of corneal infections due to M. nonliquefaciens have been published. The case is presented of a 79-year-old man with bullous keratopathy, recently affected with severe infectious keratitis. Dense, deep, and central stromal infiltrates and hyphaema were detected. After the identification of M. nonliquefaciens in the culture, and given the progression of the condition, the initial empirical treatment was modified to topical ciprofloxacin and ceftazidime in accordance with the antibiogram, combining oral ciprofloxacin and amoxicillin-clavulanate. Afte…

medicine.medical_specialtyCorneal Infectionbiologybusiness.industryInfectious Keratitismedicine.diseasebiology.organism_classificationDermatologyMoraxella nonliquefaciensKeratitisCiprofloxacinOphthalmologyLeucomamedicineBullous keratopathybusinessMoraxellamedicine.drugArchivos de la Sociedad Española de Oftalmología
researchProduct

Artificial intelligence: the unstoppable revolution in ophthalmology.

2020

Artificial Intelligence (AI) is an unstoppable force that is starting to permeate all aspects of our society as part of the revolution being brought into our lives (and into medicine) by the digital era, and accelerated by the current COVID-19 pandemic. As the population ages and developing countries move forward, AI-based systems may be a key asset in streamlining the screening, staging, and treatment planning of sight-threatening eye conditions, offloading the most tedious tasks from the experts, allowing for a greater population coverage, and bringing the best possible care to every patient. This paper presents a review of the state of the art of AI in the field of ophthalmology, focusin…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Digital eraComputer sciencePopulationAsset (computer security)Field (computer science)03 medical and health sciences0302 clinical medicineArtificial IntelligenceOphthalmologymedicineHumanseducationPandemicseducation.field_of_studybusiness.industrySARS-CoV-2Infant NewbornCOVID-19GlaucomaImage enhancementOphthalmology030221 ophthalmology & optometryArtificial intelligenceApplications of artificial intelligencebusiness030217 neurology & neurosurgeryStrengths and weaknessesSurvey of ophthalmology
researchProduct

Professional diagnostic delay in osteosarcomas of the jaws

2020

A series of 20 consecutive patients with an osteosarcoma of the jaws has been evaluated with regard to possible professional diagnostic delay. When set at an arbitrarily chosen period beyond three months, professional delay occurred in 15 patients, the mean being 21 months and the median 11 months. In five of the 15 patients a wrong diagnosis has been rendered on the biopsy specimen, being fibrous dysplasia (2x), osteoma (2x) and, in case of palatomaxillary swelling, pleomorphic adenoma (1x). In the other ten patients the initial clinicoradiographic features were misleading and apparently not indicative of a malignancy, except for one patient in whom a distinct widening of the periodontal l…

medicine.medical_specialtyDelayed DiagnosisBone NeoplasmsDelayed diagnosisMalignancyPleomorphic adenoma03 medical and health sciences0302 clinical medicineSDG 3 - Good Health and Well-beingBiopsymedicineHumansGeneral DentistryOsteomaOsteosarcomamedicine.diagnostic_testbusiness.industryResearchFibrous dysplasia030206 dentistryPrognosisMedically compromised patients in Dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseOtorhinolaryngologyUNESCO::CIENCIAS MÉDICAS/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingOsteosarcomaSurgeryRadiologybusiness
researchProduct

2017

Purpose To compare two surgical approaches for treating encapsulated blebs after trabeculectomy with mitomycin C, in terms of the development of intraocular pressure and progression of glaucoma in a long-term follow up: 1. bleb needling alone vs. 2. a combined approach of needling with additional transconjunctival scleral flap sutures, to prevent early ocular hypotony. Methods Forty-six patients with failing blebs after trabeculectomy with mitomycin C were enrolled in this study. Patients received either needling revision alone (group 1; n = 23) or a combined needling with additional transconjuctival flap sutures, if intraoperatively the intraocular pressure was estimated to be low (group 2…

medicine.medical_specialtyDry needlingIntraocular pressureMultidisciplinaryVisual acuitygenetic structuresbusiness.industrymedicine.medical_treatmentOptic diskGlaucomamedicine.diseaseeye diseasesSurgery03 medical and health sciences0302 clinical medicineOphthalmology030221 ophthalmology & optometrymedicineOptic nerveTrabeculectomysense organs030212 general & internal medicineBleb (cell biology)medicine.symptombusinessPLOS ONE
researchProduct